GPC3 and neoplasm: ACT, including chimeric antigen receptor T-cell (CAR-T) therapy targeting tumor-associated antigens (TAA) like glypican-3 (GPC3) and alpha-fetoprotein (AFP), has demonstrated encouraging results in early-phase clinical trials by specifically recognizing and eliminating tumor cells without MHC restriction (40).